# Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study

> **NCT04823247** · — · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 782 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Tildrakizumab

## Key facts

- **NCT ID:** NCT04823247
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-22
- **Primary completion:** 2025-01-09
- **Final completion:** 2025-01-09
- **Target enrollment:** 782 (ACTUAL)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04823247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04823247, "Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04823247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*